Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: pentoxyifylline, Mebeverine, ethosuximide.
- Who it may be relevant to
- Registry conditions: IBS - Irritable Bowel Syndrome. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Comparative Study to Assess Safety and Effectiveness of Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
Overview
Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome
Detailed description
Ethosuximide and pentoxifylline in the treatment of abdominal pain related to irritable bowel syndrome: Does this add to current treatment?
Interventions
- Drug pentoxyifylline
Pentoxyifylline two times daily for 3 months - Drug Mebeverine
Mebeverine 3 times for 3 months - Drug ethosuximide
ethosuximide 3 times for 3 months
Primary outcome measures
- Number of patients with improved Visual analog scales (VAS) for assessment of pain in IBS [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- • Age ≥ 18 years,
- Man and Women, Negative pregnancy test and effective contraception,
- IBS defined by the Rome criteria IV
- During the previous seven days the inclusion visit, average numeric rating scale (NRS) pain ≥ 4.
- IBS Treatment stable for 1 month
Exclusion criteria
- • Breastfeeding
- Diabetic patients
- Significant liver function abnormalities (transaminases> 3N, cholestasis) and moderate renal disease (MDRD <60 ml / min)
- Addiction to alcohol and / or drugs,
- Antiepileptic drugs taken (epilepsy or chronic pain)
- Chronic pain of greater intensity than that related to IBS,
- Known Allergyto succinimides (ethosuximide, methsuximide, phensuximide) and pentoxifylline.
- History or current severe depression (hospitalization, long-term antidepressant treatment)
- Psychotic disorders,
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Sherief Abd-Elsalam — Tanta
Publications
- El-Haggar SM, Hegazy SK, Abd-Elsalam SM, Elkaeed EB, Al-Karmalawy AA, Bahaa MM. A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial. J Inflamm Res. 2022 Feb 19;15:1159-1172. doi: 10.2147/JIR.S346608. eCollection 2022. PMID 35221706
- El-Haggar SM, Hegazy SK, M Abd-Elsalam S, Bahaa MM. Open-label pilot study of ethosuximide as adjunctive therapy for relieving abdominal pain related to Irritable Bowel Syndrome. J Clin Pharm Ther. 2022 Mar;47(3):306-312. doi: 10.1111/jcpt.13556. Epub 2021 Nov 2. PMID 34726293
Identifiers
NCT: NCT04217733 · Sherief Protocol